Annotation (Toggle Detail/Summary View) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gene-Chemical Interaction AnnotationsGene-Chemical Interaction Annotations
Gene-Chemical Interaction AnnotationsTerm | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | 17alpha-ethynylestradiol | affects expression | ISO | RGD:10440 | 6480464 | Ethinyl Estradiol affects the expression of CYP21A1 mRNA | CTD | PMID:17555576 | 17alpha-ethynylestradiol | decreases expression | ISO | RGD:10440 | 6480464 | Ethinyl Estradiol results in decreased expression of CYP21A1 mRNA | CTD | PMID:16174780 PMID:17942748 | 17alpha-ethynylestradiol | decreases expression | EXP | | 6480464 | Ethinyl Estradiol results in decreased expression of CYP21A1 mRNA | CTD | PMID:16174780 | 17alpha-ethynylestradiol | multiple interactions | ISO | RGD:10440 | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in decreased expression of CYP21A1 mRNA | CTD | PMID:17942748 | 17alpha-ethynylestradiol | decreases expression | ISO | RGD:10440 | 6480464 | Ethinyl Estradiol results in decreased expression of CYP21A1 mRNA | CTD | PMID:17942748 PMID:16174780 | 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | RGD:10440 | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in decreased expression of CYP21A1 mRNA | CTD | PMID:17942748 | 2,6-dibromophenol | decreases expression | ISO | RGD:1346271 | 6480464 | 2,6-dibromophenol results in decreased expression of CYP21A2 mRNA | CTD | PMID:17447562 | 3,3',4,4',5-pentachlorobiphenyl | increases expression | ISO | RGD:1346271 | 6480464 | 3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CYP21A2 mRNA | CTD | PMID:15703266 PMID:16216300 | 3,3',4,4',5-pentachlorobiphenyl | increases activity | ISO | RGD:1346271 | 6480464 | 3,4,5,3',4'-pentachlorobiphenyl results in increased activity of CYP21A2 protein | CTD | PMID:15703266 | 3,3',4,4',5-pentachlorobiphenyl | increases expression | ISO | RGD:1346271 | 6480464 | 3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CYP21A2 mRNA | CTD | PMID:16216300 PMID:15703266 | 3,3',5,5'-tetrabromobisphenol A | increases expression | ISO | RGD:1346271 | 6480464 | tetrabromobisphenol A results in increased expression of CYP21A2 mRNA | CTD | PMID:18313098 | 8-bromo-3',5'-cyclic AMP | increases expression | ISO | RGD:1346271 | 6480464 | 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP21A2 mRNA | CTD | PMID:22079614 PMID:22546480 | 8-bromo-3',5'-cyclic AMP | multiple interactions | ISO | RGD:1346271 | 6480464 | Mitotane inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP21A2 mRNA] | CTD | PMID:22546480 | aflatoxin B1 | increases expression | ISO | RGD:1346271 | 6480464 | Aflatoxin B1 results in increased expression of CYP21A2 mRNA | CTD | PMID:21641981 | ammonium chloride | affects expression | EXP | | 6480464 | Ammonium Chloride affects the expression of CYP21A1 mRNA | CTD | PMID:16483693 | benzo[a]pyrene | decreases expression | ISO | | 6480464 | Benzo(a)pyrene results in decreased expression of CYP21A1 mRNA | CTD | PMID:17879257 | benzo[a]pyrene | increases expression | ISO | RGD:1346271 | 6480464 | Benzo(a)pyrene results in increased expression of CYP21A2 mRNA | CTD | PMID:22316170 | benzo[a]pyrene | multiple interactions | ISO | RGD:10440 | 6480464 | [Benzo(a)pyrene co-treated with XPA gene mutant form co-treated with TRP53 gene mutant form] results in increased expression of CYP21A1 mRNA | CTD | PMID:21715664 | cadmium dichloride | decreases expression | ISO | RGD:10440 | 6480464 | Cadmium Chloride results in decreased expression of CYP21A1 mRNA | CTD | PMID:11958953 | cadmium dichloride | decreases methylation | EXP | | 6480464 | Cadmium Chloride results in decreased methylation of CYP21A1 promoter | CTD | PMID:22457795 | lycopene | decreases expression | EXP | | 6480464 | lycopene results in decreased expression of CYP21A1 mRNA | CTD | PMID:15084515 | N-ethyl-N-nitrosourea | increases expression | ISO | RGD:10440 | 6480464 | Ethylnitrosourea results in increased expression of CYP21A1 mRNA | CTD | PMID:19100860 | N-nitrosodiethylamine | multiple interactions | EXP | | 6480464 | [Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of CYP21A1 mRNA | CTD | PMID:18164116 | N-nitrosodiethylamine | increases expression | ISO | RGD:10440 | 6480464 | Diethylnitrosamine results in increased expression of CYP21A1 mRNA | CTD | PMID:19100860 | paracetamol | decreases expression | ISO | RGD:1346271 | 6480464 | Acetaminophen results in decreased expression of CYP21A2 mRNA | CTD | PMID:21420995 | perfluorooctanoic acid | affects expression | ISO | RGD:10440 | 6480464 | perfluorooctanoic acid affects the expression of CYP21A1 mRNA | CTD | PMID:18281256 | pirinixic acid | multiple interactions | ISO | RGD:1346271 | 6480464 | [pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of CYP21A2 mRNA | CTD | PMID:19710929 | tamoxifen | affects expression | ISO | RGD:10440 | 6480464 | Tamoxifen affects the expression of CYP21A1 mRNA | CTD | PMID:17555576 | tetracycline | increases expression | ISO | RGD:10440 | 6480464 | Tetracycline results in increased expression of CYP21A1 mRNA | CTD | PMID:16917069 | valproic acid | decreases expression | ISO | RGD:1346271 | 6480464 | Valproic Acid results in decreased expression of CYP21A2 mRNA | CTD | PMID:19566492 | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gene Ontology AnnotationsMolecular Pathway Annotations| External Database Links | |
| KEGG Pathway | Metabolic pathways |
| Steroid hormone biosynthesis | |
Disease Annotations
|
|
Gene-Chemical Interaction Annotations
|
|
|
Gene Ontology Annotations
|
|
|
|
Molecular Pathway Annotations
|
|
| External Database Links | |
| KEGG Pathway | Metabolic pathways |
| Steroid hormone biosynthesis | |
References - curated| 1. |
Brake PB and Jefcoate CR, Endocrinology. 1995 Nov;136(11):5034-41. |
| 2. |
Huang XJ, etal., Toxicol Lett. 2009 Dec 15;191(2-3):167-73. Epub 2009 Sep 4. |
| 3. |
Hurt P, etal., Genome Res 2004 Apr;14(4):631-9. |
| 4. |
Lovelace M, etal., Brain Res Bull 2003 Oct 15;61(6):609-15. |
| 5. |
MGD data from the GO Consortium |
| 6. |
Nishizato Y, etal., Toxicol In Vitro. 2010 Mar;24(2):677-85. Epub 2009 Aug 7. |
| 7. |
Payne AH and Hales DB, Endocr Rev. 2004 Dec;25(6):947-70. |
| 8. |
Pipeline to import KEGG annotations from KEGG into RGD Pathway Ontology |
| 9. |
RGD automated data pipeline |
| 10. |
RGD automated import pipeline for gene-chemical interactions |
| 11. |
RGD Automated Pipelines |
| 12. |
Speiser PW and White PC, N Engl J Med. 2003 Aug 21;349(8):776-88. |
| 13. |
Zhou MY, etal., J Steroid Biochem Mol Biol 1997 Jul;62(4):277-86. |
References - uncurated| PubMed | 12136338 |
RGD Disease Portals| Cyp21a1 has been annotated in the following RGD Disease Portals. |
|||||||
 |
| ||||||
 |
| ||||||
 |
| ||||||
 |
| ||||||
 |
| ||||||
 |
| ||||||
Comparative Map Data| Cyp21a1 (Rattus norvegicus) |
|
|||||||||||||||||||||||||||||||||||
| CYP21A1P (Homo sapiens) |
|
|||||||||||||||||||||||||||||||||||
| CYP21A2 (Homo sapiens) |
|
|||||||||||||||||||||||||||||||||||
| Cyp21a1 (Mus musculus) |
|
Position Markers| RH94616 |
|
||||||||||||||||||||||||||||||
| RH134814 |
|
QTLs in Region (RGSC Genome Assembly v3.4)| The following QTLs overlap with this region. |  | Full Report | | CSV | | TAB | | Printer | | Gviewer |
Nucleotide Sequences| Nucleotide RefSeqs | NM_057101 | (Get FASTA) | Search GEO for Microarray Profiles |
| GenBank Nucleotide | AABR06099863 | (Get FASTA) | Search GEO for Microarray Profiles |
| AAHX01099587 | (Get FASTA) | Search GEO for Microarray Profiles | |
| AY091790 | (Get FASTA) | Search GEO for Microarray Profiles | |
| BX883044 | (Get FASTA) | Search GEO for Microarray Profiles | |
| CH474121 | (Get FASTA) | Search GEO for Microarray Profiles | |
| U56853 | (Get FASTA) | Search GEO for Microarray Profiles | |
| U56854 | (Get FASTA) | Search GEO for Microarray Profiles |
| RefSeq Acc Id: | NM_057101 | ||||||||||||||||||||
| RefSeq Status: | VALIDATED | ||||||||||||||||||||
| Type: | CODING | ||||||||||||||||||||
| Protein Acc Id: | NP_476442 | ||||||||||||||||||||
| Position: |
|
Protein Sequences| Protein RefSeqs | NP_476442 | (Get FASTA) |
| GenBank Protein | AAD05573 | (Get FASTA) |
| AAM14720 | (Get FASTA) | |
| EDL83427 | (Get FASTA) | |
| Q64562 | (Get FASTA) |
Strain Sequence Variants
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
External Database Links| Database | Acc Id | Source(s) |
| Ensembl Genes | ENSRNOG00000000428 | ENTREZGENE, UniProtKB/TrEMBL |
| Ensembl Protein | ENSRNOP00000037516 | ENTREZGENE, UniProtKB/TrEMBL |
| Ensembl Transcript | ENSRNOT00000031548 | ENTREZGENE, UniProtKB/TrEMBL |
| Entrez Gene | 24298 | ENTREZGENE |
| Gene3D-CATH | Cyt_P450 | UniProtKB/Swiss-Prot |
| Germonline | ENSRNOG00000000428 | UniProtKB/Swiss-Prot |
| HomoloGene Group ID | 68063 | ENTREZGENE |
| InterPro | Cyt_P450 | UniProtKB/Swiss-Prot |
| Cyt_P450_CS | UniProtKB/Swiss-Prot | |
| Cyt_P450_E_grp-I | UniProtKB/Swiss-Prot | |
| IPI | IPI00213581 | UniProtKB/Swiss-Prot |
| IPI01016525 | UniProtKB/TrEMBL | |
| KEGG Report | rno:24298 | ENTREZGENE, UniProtKB/TrEMBL |
| Pfam | p450 | UniProtKB/Swiss-Prot |
| PRINTS | EP450I | UniProtKB/Swiss-Prot |
| P450 | UniProtKB/Swiss-Prot | |
| PROSITE | CYTOCHROME_P450 | UniProtKB/Swiss-Prot |
| Superfamily-SCOP | Cytochrome_P450 | UniProtKB/Swiss-Prot |
| UniGene | Rn.161726 | ENTREZGENE |
| UniProt | CP21A_RAT | UniProtKB/Swiss-Prot |
| F1LRG0_RAT | UniProtKB/TrEMBL | |
| Q8R402_RAT | UniProtKB/TrEMBL |
Nomenclature History| Date | Current Symbol | Current Name | Previous Symbol | Previous Name | Description | Reference | Status |
|---|---|---|---|---|---|---|---|
| 2010-04-19 | Cyp21a1 | cytochrome P450, family 21, subfamily a, polypeptide 1 | Cyp21a1 | cytochrome P450, subfamily 21A, polypeptide 1 | Nomenclature updated to reflect human and mouse nomenclature | 10779 | APPROVED |
| 2002-11-06 | Cyp21a1 | cytochrome P450, subfamily 21A, polypeptide 1 | Cyp21 | Cytochrome P450, subfamily XXI (steroid 21-hydroxylase) | Symbol and Name updated | 2225 | APPROVED |
| 2002-06-10 | Cyp21 | Cytochrome P450, subfamily XXI (steroid 21-hydroxylase) | Symbol and Name status set to approved | 1490 | APPROVED |
RGD Curation Notes| Note Type | Note | Reference |
|---|---|---|
| gene_expression | expressed in kidney, aorta, liver, cerebellum, hypothalamus and brain stem, heart and cerebrum, but not in hippocampus | 1298842 |
| gene_expression | expressed in astrocytes | 1298841 |
| gene_function | converts progesterone to deoxycorticosterone | 1298842 |
| gene_function | performs 21-hydroxylation of steroids in astrocytes and CNS | 1298842 |
| gene_mapping | maps to the MHC RT1 complex | 1300431 |
| gene_process | metabolizes to tetrahydrodeoxycorticosterone (THDOC), which binds to GABA receptors | 1298841 |
| More on Cyp21a1 | |
|
Entrez Gene |
|
Ensembl Gene |
| Genome Browser |
|
NCBI Map Viewer |
|
Vista |
|
Vista + UCSC |
| RGD Object Information | |
| RGD ID: | 2461 |
| Created: | 2000-05-25 |
| Species: | Rattus norvegicus |
| Last Modified: | 2013-04-16 |
| Status: | ACTIVE |
© Bioinformatics Program, HMGC at the Medical College of Wisconsin
RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.